FDA PMA FDA Class 3 Approved 🇺🇸 United States

Immunohistochemistry Assay, Antibody, Claudin 18

PMA: P230018 · Decision Oct 18, 2024
Classifications
1
FEI Numbers
1
Registration Numbers
1

Basic Information

Device Name
Immunohistochemistry Assay, Antibody, Claudin 18
Trade Name
VENTANA CLDN18 (43-14A) RxDx Assay
PMA Number
P230018
Device Class
FDA Class 3
Product Code
QZJ
Generic Name
Immunohistochemistry assay, antibody, claudin 18
Regulation Number
864.1860
Medical Specialty
Hematology
Advisory Committee
Pathology
Decision
Approved
Decision Code
APPR
Decision Date
October 18, 2024
Date Received
June 9, 2023
Expedited Review
N

Advisory Committee Statement

VENTANA CLDN18 (43-14A) RxDx Assay is a qualitative immunohistochemical assay using mouse monoclonal anti-claudin 18, clone (43-14A), intended for laboratory use in the assessment of claudin 18 (CLDN18) protein in formalin-fixed, paraffin-embedded (FFPE) gastric adenocarcinoma including gastroesophageal junction (GEJ) tissue specimens by light microscopy. This assay is used with OptiView DAB IHC Detection Kit for staining on a BenchMark ULTRA instrument.The assay is indicated as an aid in identifying patients with gastric or GEJ adenocarcinoma who may be eligible for treatment with VYLOY (zolbetuximab) in accordance with the approved therapeutic product labeling. The clinical cutoff for the therapeutic product is ? 75% viable tumor cells (% TC) demonstrating moderate to strong membrane CLDN18 staining above background. Test results of the VENTANA CLDN18 (43-14A) RxDx Assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QZJ Immunohistochemistry Assay, Antibody, Claudin 18